Fungal infections cause more than 1.5 million deaths annually and cost billions. A new vaccine from the University of Georgia could be the first clinically approved immunization to protect against them.
The new tests are expected to eventually cut costs and waiting times significantly not only in Morocco, but across the entire continent.
For decades researchers have been trying to develop a vaccine for the deadly respiratory disease. It looks like 2023 will be the landmark year where not only one, but possibly three different vaccines are approved.
In an expansion of the company’s “An Accord for a Healthier World” program, which is aimed at increasing access to innovative treatments in some of the world’s poorest countries, Pfizer said it will now offer a total of 500 products.
The lower Manhattan store is the first of 36 recently licensed dispensaries to open, with an additional 139 licenses yet to be issued and 900 applicants still awaiting word.
By creating a hairpin-shaped pair of DNA molecules, the researchers expose cancer to the immune system’s targeting procedure, and thus stop and even reverse cancer in mice.
In a study published in Pharmaceutics, scientists tested their vaccine on 60 rats. The immunized animals could produce antibodies that stop the deadly drug’s effects.
The U.S. conglomerate has set a 2025 deadline to stop producing PFAS, the “forever chemicals” used in anything from cell phones to semiconductors that have been linked to cancer and other health problems.
Over the past decade, rubella cases have decreased dramatically in the Western Pacific Region, as millions of babies and young children have been reached with vaccines.
The Phase 1/2 trial data from Janssen Research & Development covered hundreds of myeloma patients. Based on preliminary trial data, the FDA has granted it “Breakthrough Therapy” designation.
